MDxHealth SA

Industry

  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
    • Drug Discovery Technologies
      • ADMET
  • Services
  • In Vitro Diagnostics
    • Therapeutic Drug Monitoring
    • Saliva-based Testing
    • Molecular Diagnostics & Genetic Testing
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools

Other Names/Subsidiaries

  • MDxHealth BV
  • MDxHealth PharmacoDx
  • MDxHealth
  • NovioGendix Holding
  • OncoMethylome Sciences
  • Oncotype DX
See more in Biomedtracker

Latest on MDxHealth SA

In Vivo

Financing Quarterly Statistics, Q3 2024

 
• By Maureen Riordan and Deanna Kamenski

Biopharma financing during the third quarter of 2024 totaled $17bn from 207 deals. Of those, 54 reached $100m or more. The follow-on public offering (FOPO) category made up the made up most (34%) of t

In Vivo

Dealmaking Quarterly Statistics, Q3 2022

 
• By Deanna Kamienski and Maureen Riordan

Biopharma Acquisitions Biopharma merger and acquisition value for the third quarter of 2022 reached $15.4bn from 41 transactions, 21 of which had disclosed values. Four M&A transactions hit or exceede

Medtech Insight

Market Intel: Precision Diagnostics And Focal Treatments Offer Personalized Approach To Prostate Cancer

 
• By Phil Greenfield

The combined market for prostate cancer diagnostics and minimally invasive treatments is set to increase from $900m to $1.46bn in the next five years. But conservative treatment, or watchful waiting,

Medtech Insight

MDx Health Signs Exclusive Canadian Agreement

 
• By Catherine Longworth

MDxHealth SA has signed an exclusive distribution agreement with Canadian lab-testing company LifeLabs to make its SelectMDx prostate cancer test available in Canada, the companies announced Feb. 1